Denosumab (Dmab), a RANKL blocking antibody that mimics the effects of OPG, has been demonstrated to reduce the risk of fractures and is widely used in the treatment of osteoporosis (McCloskey et al., 2012). This evidence concerns the gene TNFSF11 and osteoporosis.